In the preceding three months, 7 analysts have released ratings for Kymera Therapeutics (NASDAQ:KYMR), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 4 | 3 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 2 | 0 | 0 |
| 3M Ago | 0 | 1 | 1 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $50.29, a high estimate of $65.00, and a low estimate of $36.00. Witnessing a positive shift, the current average has risen by 26.36% from the previous average price target of $39.80.
Analyzing Analyst Ratings: A Detailed Breakdown
The standing...
Login or create a forever free account to read this news
Sign up/Log in
